“Institutional Cost Savings through Dose Banding Strategy of Pembrolizumab in Oncology Patients: A Real-World Data Analysis”. 2025. Universitas Scientiarum, November, S19. https://doi.org/10.11144/Javeriana.SCSI30.icst.